Galecto, Inc. Overview
Pro stress-test →Galecto is a clinical-stage biopharmaceutical company focused on developing novel treatments for cancer and liver diseases, with an increasing emphasis on hematological malignancies. The company completed the acquisition of Damora Therapeutics in November 2025, and announced a name change to Damora Therapeutics in March 2026, repositioning its focus toward advancing disease-modifying biologics for blood cancers driven by mutant calreticulin.
Strategic Profile
Pro stress-test →A concurrent private placement of Series C non-voting convertible preferred stock in November 2025 resulted in approximately $284.9 million in gross proceeds and is expected to fund operations into 2029. With multiple programs with best-in-class potential on track to enter clinical development in 2026, the company aims to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes.
Competitive Landscape
Pro stress-test →Galecto is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is significant medical need for disease-modifying treatments. Direct competitors in the mutCALR space are limited; broader competitors include oral FLT3 and menin inhibitors (ruxolitinib, fedratinib, and investigational menin inhibitors) for MPN/ET treatment. Galecto's antibody-based approach targets an underserved patient population with no approved disease-modifying mutCALR therapies.
Industry Context
Galecto, Inc. operates in Oncology biologics development.
Key facts
Founded: 2011 · Headquarters: Boston, Massachusetts · Employees: 30 · Revenue: $0 · Market cap: N/A